Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06341712 | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma(CabOSTar) | terminated | Phase 2 | 10 | IpsenINDUSTRY | 10 | Mar 31, 2026 | clinicaltrials |
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH |
| 1 |
| Feb 18, 2026 |
| clinicaltrials |
| NCT05496569 | TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | terminated | Phase 2 | 26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy | terminated | Phase 2 | 110 | Washington University School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 | clinicaltrials |
| NCT05580588 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas | terminated | Phase 2 | 14 | Shanghai Pharma Biotherapeutics USA Inc.INDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03016091 | A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma | terminated | Phase 2 | 18 | Rabin Medical CenterOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma(TTI-621-03) | terminated | Phase 2 | 76 | PfizerINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03291054 | Epacadostat and Pembrolizumab in Patients With GIST | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05160168 | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 1 / Phase 2 | 32 | Theseus PharmaceuticalsINDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04938180 | A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients | terminated | Phase 2 | 4 | AmMax Bio, Inc.INDUSTRY | 3 | May 24, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT05116683 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma(ATX-101) | terminated | Phase 2 | 4 | Benjamin IzarOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02232620 | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | terminated | Phase 2 | 2 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04365660 | 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma | terminated | Phase 2 | 1 | Davidzon, Guido, M.D.OTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | terminated | Phase 1 / Phase 2 | 12 | Y-mAbs TherapeuticsINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT00543712 | A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) | terminated | Phase 2 | 15 | Genentech, Inc.INDUSTRY | 2 | Dec 13, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03442985 | An Efficacy and Safety Study of Palovarotene for the Treatment of MO(MO-Ped) | terminated | Phase 2 | 193 | Clementia Pharmaceuticals Inc.INDUSTRY | 12 | Aug 1, 2022 | clinicaltrials |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03041701 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Apr 14, 2022 | clinicaltrials |
| NCT00972335 | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | terminated | Phase 2 | 18 | SCRI Development Innovations, LLCOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01759303 | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | terminated | Phase 2 | 12 | Emerald Clinical Inc.INDUSTRY | 1 | Apr 13, 2021 | clinicaltrials |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial(APLIPO) | terminated | Phase 2 | 24 | Institut BergoniéOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03013127 | A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery(PROMO) | terminated | Phase 2 | 12 | Oslo University HospitalOTHER | 2 | Oct 14, 2020 | clinicaltrials |
| NCT03509207 | Vorinostat (SAHA) in Uterine Sarcoma | terminated | Phase 2 | 3 | Medical University of GrazOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | terminated | Phase 2 | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00752206 | A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung | terminated | Phase 2 | 38 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | terminated | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 27, 2019 | clinicaltrials |
| NCT01886105 | Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT02441309 | A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)(MEMOS) | terminated | Phase 2 | 8 | University of OxfordOTHER | 5 | Sep 13, 2019 | clinicaltrials |
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | terminated | Phase 2 | 20 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02718482 | Phase II Trial for the Treatment of Relapsed Osteosarcoma(OsteoREC2015) | terminated | Phase 2 | 7 | Italian Sarcoma GroupNETWORK | 1 | May 13, 2019 | clinicaltrials |
| NCT00414076 | Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01986829 | Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy | terminated | Phase 2 | 9 | Washington University School of MedicineOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT00617890 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | terminated | Phase 2 | 219 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | terminated | Phase 1 / Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00003483 | Antineoplaston Therapy in Treating Patients With Meningioma | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01391611 | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 2 | 25 | Kristen GanjooOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT01089595 | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | terminated | Phase 2 | 5 | Fox Chase Cancer CenterOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Mar 31, 2026source: clinicaltrials